Skip to main content
S&P 5007,675.36+0.68%DOW52,297.03+0.16%NASDAQ26,188.61+0.90%BTC$80,162.00-0.69%ETH$2,322.26-1.46%GOLD$4,037.80+0.75%OIL$102.07-1.16%
Smart Investors Daily
SID Premium
CM

NASDAQ · CMPS

COMPASS Pathways plc

Healthcare · Medical - Care Facilities

$11.18

Up+$0.01 (+0.09%)

Updated Oct 26, 2026, 4:55 PM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
667.21M
P/E ratio
-2.79
Dividend yield
0.00%
52-week range
$4.88 – $15.87
Volume
1.16M
Avg. volume
1.76M

Price performance · CMPS

CMPS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 23, 2026

CMPS closed at $11.18 after 20 trading sessions, down 15.50% for the selected period.

Last close
$11.18
Period change
-15.50%
Period low
$10.75
Period high
$13.23
Daily close
View OHLC price history
CMPS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 23, 2026$11.45$11.515$11.02$11.181.16M
Oct 22, 2026$11.73$11.9699$11.4299$11.631.34M
Oct 21, 2026$12.00$12.12$11.77$11.841.83M
Oct 20, 2026$11.11$12.0441$11.065$11.903.35M
Oct 19, 2026$10.87$11.17$10.81$11.113.28M
Oct 16, 2026$11.51$11.60$10.72$10.754.97M
Oct 15, 2026$11.25$11.695$11.15$11.622.81M
Oct 14, 2026$11.09$11.50$10.97$11.272.54M
Oct 13, 2026$11.54$11.54$11.11$11.141.88M
Oct 12, 2026$12.02$12.05$11.53$11.531.96M
Oct 9, 2026$11.685$12.075$11.42$12.002.28M
Oct 8, 2026$11.695$11.79$11.1304$11.472.83M
Oct 7, 2026$11.50$11.86$11.45$11.691.59M
Oct 6, 2026$11.72$11.80$11.17$11.562.8M
Oct 5, 2026$12.00$12.0568$11.27$11.603.77M
Oct 2, 2026$12.00$12.0699$11.63$11.902.66M
Oct 1, 2026$12.38$12.46$11.82$11.953.89M
Sep 30, 2026$13.11$13.15$12.42$12.443.05M
Sep 29, 2026$13.31$13.31$12.84$12.962.5M
Sep 28, 2026$13.10$13.49$12.82$13.231.78M

Latest CMPS news

The latest Smart Investors Daily articles mentioning CMPS.

Stock researchCompany · Overview

CMPS research

Overview

Company profile and research snapshot.

Company profile

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.00
Implied upside
—
Analysts
—
CMPS recent ratings
DateFirmRatingTarget
Aug 7, 2026HC Wainwright & Co.Buy—
Aug 6, 2026RBC CapitalOutperform—
Aug 6, 2026Morgan StanleyOverweight—
Aug 6, 2026B. Riley SecuritiesBuy—
Jul 27, 2026Wells FargoEqual-Weight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 18, 2026

COMPASS Pathways (CMPS) Stock May Trade At A Premium After Positive Phase 3 Results

COMPASS Pathways has delivered a powerful 3 year share price gain, even after a recent pullback, and fresh clinical progress on its lead therapy now puts the spotlight on whether that move still lines up with the company’s balance sheet. With the stock last closing at US$10.75, the open question is how much of that price can be grounded in book value rather than story alone. Over the past 3 years the share price has risen about 85.7%, which puts real weight on whether the current valuation...

Yahoo · Oct 14, 2026

Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day

LONDON & JERSEY CITY, N.J., October 14, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the first-ever TRD Awareness Day in the U.S., a day dedicated to recognizing and advocating for individuals, caregivers and communities impacted by TRD. The campaign is being amplified by leading mental health organizations, including National Alliance on Mental Illness (NAMI), Mental Health

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By